Ziping Wang

3.7k citations
118 papers · 2.6k · 4 hit papers · h-index 25

Impact in

  • Oncology top 5%
    • Lung Cancer Research Studies
    • Cancer Immunotherapy and Biomarkers
    • Colorectal Cancer Treatments and Studies
    • Lung Cancer Treatments and Mutations
    • Lung Cancer Diagnosis and Treatment

Papers in

    • Lung Cancer Treatments and Mutations 41
    • Lung Cancer Diagnosis and Treatment 13
    • Gastric Cancer Management and Outcomes 5
    • Lung Cancer Research Studies 15
    • Cancer Immunotherapy and Biomarkers 10
    • Colorectal Cancer Treatments and Studies 3

Ziping Wang

110 papers receiving 2.5k citations

Ziping Wang's Hit Papers

Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial 2023 · 149 citations
1490+1+3Years since publication50100150200

Peers

Ziping Wang
Comparison fields: 5 of 110
  • Oncology 969
  • Pulmonary and Respiratory Medicine 1.1k
  • Orthopedics and Sports Medicine 110
  • Cancer Research 175
  • Molecular Biology 467
Replace Liyun Cao with:
Liyun Cao United States
Zhiwen Chen China
Kazuhito Kawabata Japan
Loredana Santo United States
Takashi Saika Japan
Yangbai Sun China
Christopher Jon Matheny United States
Huiyong Chen China
Zhen Liu China
Liping Zhuang China
Ziping Wang relative to Liyun Cao United States Liyun Cao's profile →
Citations per field
00.5×10×20×30×37×
Liyun Cao · 1×
Citations per year

Countries citing papers authored by Ziping Wang

Since Specialization
Citations

This map shows the geographic impact of Ziping Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ziping Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ziping Wang more than expected).

Fields of papers citing papers by Ziping Wang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ziping Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ziping Wang. The network helps show where Ziping Wang may publish in the future.

Co-authors

The 25 scholars most cited alongside Ziping Wang, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Ziping Wang Line = papers co-authored together Ziping Wang links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 118 papers — load more, or switch the sort, to bring in the rest.

#Work
1
AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon–Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations
Hit paper breakdown →
2022209
2
Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase−Positive Non–Small Cell Lung Cancer
Hit paper breakdown →
2021187
3
Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial
Hit paper breakdown →
2023149
4
Toripalimab Plus Chemotherapy for Patients With Treatment-Naive Advanced Non–Small-Cell Lung Cancer: A Multicenter Randomized Phase III Trial (CHOICE-01)
Hit paper breakdown →
2022136
5 2020124
6 2021104
7 202286
8 202084
9 201984
10 201479
11 201562
12 202153
13 202353
14 202246
15 202446
16 201544
17 202138
18 201637
19 201831
20 201331

About Ziping Wang

Ziping Wang is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Cancer Research, Orthopedics and Sports Medicine and Molecular Biology, having authored 118 papers that have together received 2.6k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (41 papers), Lung Cancer Research Studies (15 papers), Lung Cancer Diagnosis and Treatment (13 papers), Cancer Immunotherapy and Biomarkers (10 papers), Gastric Cancer Management and Outcomes (5 papers), Nutritional Studies and Diet (3 papers), Colorectal Cancer Treatments and Studies (3 papers) and Cancer Genomics and Diagnostics (2 papers). The work is most often cited by research in Oncology (969 citations), Pulmonary and Respiratory Medicine (1.1k citations), Orthopedics and Sports Medicine (110 citations), Cancer Research (175 citations) and Molecular Biology (467 citations). Ziping Wang has collaborated with scholars based in China, Ethiopia and United States. Frequent co-authors include Minglei Zhuo, Tongtong An, Shengli Xia, Huizhong Wang, Meina Wu, Xue Yang, Yujia Chi, Jun Zhao, Jia Zhong and Jianjie Li. Their work appears in journals such as Journal of Thoracic Oncology, Cancer Medicine, BMC Cancer, Journal of Clinical Oncology and 癌症:英文版.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact